Skip to main content
    P

    Phathom Pharmaceuticals Inc (PHAT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.88
    -0.18 (-2.97%)

    Market Cap: $492.63M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Phathom Pharmaceuticals Inc (PHAT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Phathom Pharmaceuticals are Prothena Corporation (PRTA), X4 Pharmaceuticals (XFOR) and DiaMedica Therapeutics (DMAC). By market cap, Phathom Pharmaceuticals ranks 4th of the 13 companies on this page; Pharming Group NV (PHAR) is the largest at $891.80M. The median P/E of the 3 companies with a P/E is 39.3x.

    Peer Comparison

    PHAT's ROIC of 11.4% is above the peer median of -34.8%, and its revenue growth of 71.1% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Phathom Pharmaceuticals (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    X4 Pharmaceuticals Inc (XFOR)$318.59MN/A21.7x0.0%-36.9%63.1%0.00%
    DiaMedica Therapeutics Inc (DMAC)$474.29MN/AN/A0.0%N/A0.0%0.00%
    Pharming Group NV (PHAR)$891.80M39.3x2.4x6.3%7.9%20.8%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Tectonic Therapeutic, Inc. (TECX)$413.27MN/AN/A0.0%N/A0.0%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Puma Biotechnology Inc (PBYI)$401.70M15.0x1.6x10.3%N/A1.1%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Fennec Pharmaceuticals Inc (FENC)$410.25M159.5x6.8x3.0%N/A57.3%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Peer median$416.14M39.3x7.3x0.0%-34.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Phathom Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    X4 Pharmaceuticals Inc (XFOR)
    X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development...
    XFOR competitors
    DiaMedica Therapeutics Inc (DMAC)
    DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
    DMAC competitors
    Pharming Group NV (PHAR)
    Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States...
    PHAR competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Tectonic Therapeutic, Inc. (TECX)
    Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel...
    TECX competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Puma Biotechnology Inc (PBYI)
    Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States...
    PBYI competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Fennec Pharmaceuticals Inc (FENC)
    Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States.
    FENC competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors

    Frequently Asked Questions About PHAT

    Who are Phathom Pharmaceuticals' main competitors?

    The companies most similar to Phathom Pharmaceuticals include Prothena Corporation (PRTA), X4 Pharmaceuticals (XFOR), DiaMedica Therapeutics (DMAC), Pharming Group NV (PHAR) and Fulcrum Therapeutics (FULC), listed from the closest match.

    Who is Phathom Pharmaceuticals' biggest competitor?

    Pharming Group NV (PHAR) is the largest of the similar companies at $891.80M; Prothena Corporation (PRTA) is the closest match by business profile, size, sector and industry.

    How does PHAT stock compare with its competitors?

    PHAT's P/S is 1.8x against a peer median of 7.3x; its net margin is -30.2% against a peer median of 0.0%.

    Which of Phathom Pharmaceuticals' competitors pays a higher dividend?

    Phathom Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Phathom Pharmaceuticals bigger than its competitors?

    No. Phathom Pharmaceuticals is 4th by market cap among the 13 companies on this page; the largest is Pharming Group NV (PHAR) at $891.80M.